Elizabeth A Bayliss, Glenn K Goodrich, Jennifer C Barrow, Bill Harding, Courtney A Ripley, Courtney R Kraus, Valerie Paolino, Jonathan D Norton, Orla C Sheehan, Linda A Weffald, Ariel R Green, Ted E Palen, Emily Reeve, Matthew L Maciejewski, Cynthia M Boyd
{"title":"Discontinuation Categories Underlying Gaps in Dispensing for Six Medication Groups.","authors":"Elizabeth A Bayliss, Glenn K Goodrich, Jennifer C Barrow, Bill Harding, Courtney A Ripley, Courtney R Kraus, Valerie Paolino, Jonathan D Norton, Orla C Sheehan, Linda A Weffald, Ariel R Green, Ted E Palen, Emily Reeve, Matthew L Maciejewski, Cynthia M Boyd","doi":"10.1002/pds.70142","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Accurately identifying medication discontinuations at scale is important for developing evidence about deprescribing. Gaps in dispensing often serve as proxies for discontinuation but are imprecise. We categorize reasons for gaps in dispensing to inform data-based methods to accurately identify medication discontinuations.</p><p><strong>Methods: </strong>Using pharmacy dispensing data, we purposively sampled from a population of adults age 65+ with 2+ chronic conditions who experienced a 90-day gap in dispensing-with and without subsequent fills-of oral diabetes drugs, statins, proton pump inhibitors, drugs with anticholinergic properties, anticoagulants and antiplatelet drugs, or antihypertensives. We reviewed clinical documentation (e.g., visit notes, communications, medication orders) from last dispensing through the 90-day gap plus 120 days to classify dispensing gaps as true discontinuations (clinically intended) or non-discontinuations (no evidence of intent to discontinue), and then into subcategories. Medications with no documented explanation for the gap in dispensing and continued listing on the patient's medication list were classified as non-discontinuations.</p><p><strong>Results: </strong>Of N = 1906 records reviewed, there were 1068 (56%) true discontinuations and 838 (44%) non-discontinuations. Subcategories within true discontinuations included provider intent to discontinue, provider substitutions, intentional stops followed by restarts, and agreeing with a colleague's or patient's decision to discontinue. Non-discontinuations included documented low adherence, changes in dose, changes in pharmacy formulary, and changes in drug formulation. Proportions of drugs in categories and subcategories varied by medication group.</p><p><strong>Conclusion: </strong>Using gaps in dispensing as proxy measures for medication discontinuation may introduce bias through misclassification, and varied reasons for discontinuation may complicate causal interpretations.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 4","pages":"e70142"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70142","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Accurately identifying medication discontinuations at scale is important for developing evidence about deprescribing. Gaps in dispensing often serve as proxies for discontinuation but are imprecise. We categorize reasons for gaps in dispensing to inform data-based methods to accurately identify medication discontinuations.
Methods: Using pharmacy dispensing data, we purposively sampled from a population of adults age 65+ with 2+ chronic conditions who experienced a 90-day gap in dispensing-with and without subsequent fills-of oral diabetes drugs, statins, proton pump inhibitors, drugs with anticholinergic properties, anticoagulants and antiplatelet drugs, or antihypertensives. We reviewed clinical documentation (e.g., visit notes, communications, medication orders) from last dispensing through the 90-day gap plus 120 days to classify dispensing gaps as true discontinuations (clinically intended) or non-discontinuations (no evidence of intent to discontinue), and then into subcategories. Medications with no documented explanation for the gap in dispensing and continued listing on the patient's medication list were classified as non-discontinuations.
Results: Of N = 1906 records reviewed, there were 1068 (56%) true discontinuations and 838 (44%) non-discontinuations. Subcategories within true discontinuations included provider intent to discontinue, provider substitutions, intentional stops followed by restarts, and agreeing with a colleague's or patient's decision to discontinue. Non-discontinuations included documented low adherence, changes in dose, changes in pharmacy formulary, and changes in drug formulation. Proportions of drugs in categories and subcategories varied by medication group.
Conclusion: Using gaps in dispensing as proxy measures for medication discontinuation may introduce bias through misclassification, and varied reasons for discontinuation may complicate causal interpretations.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.